{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "vascular:dvt:thrombolysis",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-05T02:40:00.000Z",
    "contributors": [
      "vascular-surgery-agent",
      "quality-enhancement-agent"
    ],
    "status": "peer-reviewed",
    "confidence": 0.95,
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/deep-vein-thrombosis",
    "type": "procedure",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Catheter-Directed Thrombolysis for DVT",
    "definition": "Endovascular technique for treating acute iliofemoral deep vein thrombosis using catheter-delivered thrombolytic agents, with or without pharmacomechanical thrombectomy. Aims to reduce thrombus burden, restore venous patency, preserve valve function, and prevent post-thrombotic syndrome.",
    "clinical_features": {
      "rationale": {
        "goals": [
          "Rapid clot resolution",
          "Preserve venous valve function",
          "Prevent post-thrombotic syndrome (PTS)",
          "Relieve acute symptoms"
        ],
        "pts_prevention": {
          "mechanism": "Anticoagulation alone \u2192 clot organization \u2192 valve destruction \u2192 PTS",
          "incidence_with_ac": "20-50% develop PTS with anticoagulation alone",
          "severe_pts": "5-10% develop severe PTS"
        }
      },
      "patient_selection": {
        "ideal_candidates": {
          "anatomy": "Iliofemoral DVT (proximal)",
          "duration": "Symptom onset <14 days (acute)",
          "symptoms": "Severe symptoms, limb-threatening",
          "life_expectancy": ">1 year",
          "functional_status": "Good baseline function"
        },
        "absolute_contraindications": [
          "Active or recent major bleeding",
          "Recent stroke (<3 months)",
          "Recent major surgery or trauma (<10 days)",
          "Intracranial tumor or AVM",
          "Known bleeding diathesis"
        ],
        "relative_contraindications": [
          "Recent minor surgery",
          "Severe hypertension",
          "Pregnancy (relative)",
          "Age >80 (relative)"
        ]
      },
      "techniques": {
        "catheter_directed_thrombolysis": {
          "access": "Popliteal or posterior tibial vein (ultrasound guided)",
          "catheter": "Multi-sidehole infusion catheter embedded in clot",
          "agents": {
            "tpa": "0.5-1.0 mg/hr",
            "urokinase": "120,000 units/hr (less common now)"
          },
          "duration": "12-48 hours typical",
          "monitoring": "ICU, fibrinogen q6h, PTT"
        },
        "pharmacomechanical_thrombectomy": {
          "definition": "Combines thrombolysis with mechanical disruption",
          "devices": [
            "AngioJet (rheolytic)",
            "EKOS (ultrasound-enhanced)",
            "ClotTriever (mechanical aspiration)",
            "Indigo (aspiration)"
          ],
          "advantages": [
            "Faster clot resolution",
            "Lower lytic dose",
            "Shorter procedure time"
          ]
        }
      },
      "adjunctive_procedures": {
        "iliac_vein_stenting": {
          "indication": "May-Thurner syndrome or residual stenosis",
          "technique": "Self-expanding stent, oversized 1-2mm",
          "timing": "Same session or staged"
        },
        "ivc_filter": {
          "indication": "Contraindication to anticoagulation",
          "type": "Retrievable preferred",
          "retrieval": "Within 30-90 days"
        }
      },
      "outcomes": {
        "attract_trial": {
          "design": "RCT of CDT + anticoagulation vs anticoagulation alone",
          "primary_outcome": "No difference in PTS at 24 months",
          "criticism": [
            "Included femoropopliteal DVT",
            "High crossover",
            "Inconsistent technique"
          ],
          "subgroup": "Possible benefit in iliofemoral-only subgroup"
        },
        "observational_data": {
          "patency": "70-90% at 1 year with stenting",
          "pts_reduction": "Some series show reduced severe PTS"
        }
      },
      "complications": {
        "bleeding": {
          "minor": "Access site hematoma (15-20%)",
          "major": "2-10%",
          "intracranial": "<1%"
        },
        "other": [
          "Pulmonary embolism",
          "Recurrent thrombosis",
          "Access site thrombosis"
        ]
      }
    },
    "diagnostic_codes": {
      "icd10": [
        "I82.40",
        "I82.42"
      ],
      "cpt": [
        "37187",
        "37188",
        "37212"
      ]
    },
    "statement": "Catheter-Directed Thrombolysis for DVT is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Deep-Vein-Thrombosis that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Catheter-Directed Thrombolysis for DVT helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Catheter-Directed Thrombolysis for DVT include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Catheter-Directed Thrombolysis for DVT."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Apply appropriate patient selection criteria for CDT",
      "Compare catheter-directed thrombolysis and pharmacomechanical techniques",
      "Interpret ATTRACT trial results in clinical context"
    ],
    "clinical_pearls": [
      "Symptom duration <14 days and iliofemoral location are key selection criteria",
      "ATTRACT trial didn't show PTS benefit overall, but iliofemoral subgroup may benefit",
      "Pharmacomechanical devices reduce lytic dose and treatment time",
      "Always look for underlying May-Thurner syndrome and stent if present",
      "Check fibrinogen every 6 hours during lytic infusion"
    ],
    "evidence_basis": [
      "ATTRACT Trial (Circulation 2017)",
      "CaVenT Trial (Lancet 2012)"
    ]
  },
  "semantic_relations": {
    "skos:broader": [
      "vascular:dvt:treatment-overview"
    ],
    "skos:narrower": [
      "vascular:dvt:pharmacomechanical",
      "vascular:dvt:ultrasound-assisted"
    ],
    "skos:related": [
      "vascular:dvt:iliofemoral",
      "vascular:may-thurner:definition",
      "vascular:dvt:pts"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Catheter-Directed Thrombolysis for DVT. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Catheter-Directed_Thrombolysis_for_DVT",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}